Page 308 - 《软件学报》2021年第12期

3972 Journal of Software 软件学报 Vol.32, No.12, December 2021

致谢 在此,我们向对本文工作提供帮助和支持的同行以及对本文提出宝贵意见的各位审稿专家表示衷心的
感谢.

References:
[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality
worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 2018,68(6):394−424. https://doi.org/10.3322/caac.
21492
[2] National Cancer Institute. HPV and cancer. http://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-fact-
sheet
[3] Moscicki AB, Schiffman M, Kjaer S, et al. Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine,
2006,24(Suppl.):S3,S42−S51.
[4] Cheng X, Cai S, Li Z, et al. The prognosis of women with stage IB1~IIB node-positive cervical carcinoma after radical surgery.
Word Journal of Surgical Oncology, 2004,2(1):1−8.
[5] Edge SB, Compton CC. The American joint committee on cancer: The 7th edition of the AJCC cancer staging manual and the
future of TNM. Annals of Surgical Oncology, 2010,17(6):1471−1474.
[6] Bhatla N, Berek JS, Fredes MC, et al. Revised FIGO staging for carcinoma of the cervix uteri. Int’l Journal of Gynecology &
Obstetrics, 2019, 145(1):129−135.
[7] Coit DG, Thompson JA, Algazi A, et al. Melanoma, version 2.2016, NCCN clinical practice guidelines in oncology. Journal of the
National Comprehensive Cancer Network, 2016,14(4):450−473.
[8] Gien LT, Covens A. Fertility-sparing options for early stage cervical cancer. Gynecologic Oncology, 2010,117(2):350−357.
[9] Bogaerts J, Ford R, Sargent D, et al. Individual patient data analysis to assess modifications to the RECIST criteria. European
Journal of Cancer, 2009,45(2):248−260.
[10] Patankar SS, Tergas AI, Deutsch I, et al. High versus low-dose rate brachytherapy for cervical cancer. Gynecologic Oncology,
2015,136(3):534−541.
[11] Li X, Duan JJ, Kong WM. Advances in research on chemosensitivity and cross-tolerance of cervical cancer. Journal of Chinese
Oncology, 2019,25(1):67−70 (in Chinese with English abstract).
[12] Bhosale PR, Iyer RB, Ramalingam P, et al. Is MRI helpful in assessing the distance of the tumour from the internal os in patients
with cervical cancer below FIGO Stage IB2? Clinical Radiology, 2016, 71(6):515−522.
[13] Devine CE, Viswanathan C, Faria SD, et al. Imaging and staging of cervical cancer. Seminars in Ultrasound, CT and MRI,
2019,40(4):280−286.
[14] Breiman L. Random forests. Machine Learning, 2001,45(1):5−32.
[15] Kim JH, Kim CK, Park BK, et al. Dynamic contrast-enhanced 3-T MR imaging in cervical cancer before and after concurrent
chemoradiotherapy. European Radiology, 2012,22(11):2533−2539.
[16] Liu WF, Xu F, Wu M. Predictive value of DCE-MRI 4D-tissue technical quantitative parameters in evaluating the efficacy of
radiotherapy and chemotherapy for cervical cancer. Practical Oncology Journal, 2016,30(3):225−228 (in Chinese with English
abstract).
[17] Dong LX, Li X, Yang S, et al. Model study of texture analysis based on DW-MRI to predict the chemoradiosensitivity in cervical
cancer. Medical Recapitulate, 2018,24(11):2270−2274 (in Chinese with English abstract).
[18] Fu ZZ, Peng Y, Cao LY, et al. Value of apparent diffusion coefficient (ADC) in assessing radiotherapy and chemotherapy success
in cervical cancer. Magnetic Resonance Imaging, 2015,33(5):516−524.
[19] Kuang F, Yan Z, Wang J, et al. The value of diffusion-weighted MRI to evaluate the response to radiochemotherapy for cervical
cancer. Magnetic Resonance Imaging, 2014,32(4):342−349.
[20] Makino H, Kato H, Furui T, et al. Predictive value of diffusion-weighted magnetic resonance imaging during chemoradiotherapy
for uterine cervical cancer. Journal of Obstetrics and Gynaecology Research, 2014,40(4):1098−1104.
[21] Ma WL, Huan Y, Wei WC, et al. The applied research of 3.0 T MRI and DWI in monitoring therapeutic effect of uterine cervix
cancer with radiotherapy. Journal of Clinical Radiology, 2009,28(12):67−70 (in Chinese with English abstract).